<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00786305</url>
  </required_header>
  <id_info>
    <org_study_id>NATB-2004</org_study_id>
    <nct_id>NCT00786305</nct_id>
  </id_info>
  <brief_title>Nebulized Ceftazidime and Amikacin in Ventilator Associated Pneumonia</brief_title>
  <official_title>Assessment of Efficiency of Nebulized Ceftazidime and Amikacin in Treatment of Ventilator Associated Pneumonia Caused by Pseudomonas Aeruginosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Hospitalier Pitie-Salpetriere</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pseudomonas aeruginosa is one of the major causative microorganisms of ventilator-associated
      pneumonia often resistant to antibiotics. In experimental models, nebulization of antibiotics
      delivers high lung tissue concentrations of antibiotics in infected lungs and increases lung
      bacterial killing. The aim of the study is to assess the efficiency of nebulized ceftazidime
      and amikacin in the treatment of pneumonia caused by Pseudomonas aeruginosa in ventilated
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bacterial killing</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of lung aeration</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>1: nebulized ceftazidime and amikacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2: intravenous ceftazidime and amikacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftazidime and amikacin</intervention_name>
    <description>Nebulized ceftazidime 15 mg/kg/3h during 8 days and nebulized amikacin 25 mg/kg/day during 3 days</description>
    <arm_group_label>1: nebulized ceftazidime and amikacin</arm_group_label>
    <other_name>fortum and amiklin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftazidime and amikacin</intervention_name>
    <description>Intravenous infusion of ceftazidime 30 mg/kg over 30 min followed by continuous infusion 90 mg/kg/day during 8 days and intravenous infusion of amikacin 15 mg/kg/day over 30 min during 3 days</description>
    <arm_group_label>2: intravenous ceftazidime and amikacin</arm_group_label>
    <other_name>fortum and amiklin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female &gt;18 years old, ventilator associated pneumonia caused by pseudomonas
             aeruginosa

          -  Written informed consent provided by the relatives

        Exclusion Criteria:

          -  Pseudomonas aeruginosa resistant to ceftazidime and amikacin

          -  Pseudomonas aeruginosa pneumonia associated with other infections requiring
             intravenous treatment

          -  Severe septic shock and severe hypoxemia

          -  Allergy to ceftazidime or amikacin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Jacques Rouby, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>La Pitie-Salpetriere hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Intensive care unit, Department of anesthesiology, La pitie-Salpetriere hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2008</study_first_submitted>
  <study_first_submitted_qc>November 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2008</study_first_posted>
  <last_update_submitted>November 5, 2008</last_update_submitted>
  <last_update_submitted_qc>November 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2008</last_update_posted>
  <responsible_party>
    <name_title>Jean-Jacques Rouby</name_title>
    <organization>Groupe Hospitalier Pitie-Salpetriere</organization>
  </responsible_party>
  <keyword>Nebulization</keyword>
  <keyword>ceftazidime</keyword>
  <keyword>amikacin</keyword>
  <keyword>pneumonia</keyword>
  <keyword>Pseudomonas aeruginosa</keyword>
  <keyword>mechanical ventilation</keyword>
  <keyword>Ventilator-associated pneumonia</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amikacin</mesh_term>
    <mesh_term>Ceftazidime</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

